Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 19/20 | 0.74 |
| ▸ | CAPNS1 | P04632 | 16/20 | 0.74 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705665 | 0.92 | CAPN1 (0.64) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL4806800 | 0.91 | CAPN1 (0.82) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL4621441 | 0.91 | CAPN1 (0.90) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL4622780 | 0.89 | CAPN1 (0.81) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL4622691 | 0.85 | CAPN1 (1.00) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL4622529 | 0.84 | CAPN1 (1.00) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL4620489 | 0.84 | CAPN1 (0.76) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL5970894 | 0.83 | CAPN1 (0.71) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL4621787 | 0.83 | CAPN1 (1.00) | CAPN1CAPNS1CASP1CASP3CASP7 | |
| SCHEMBL4622119 | 0.82 | CAPN1 (1.00) | CAPN1CAPNS1CASP1CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701974-B1 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOD CONSEILS RECH APPLIC (FR) | 2008-03-26 | — | — | EP | disclosed |